Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

NCT04548791 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision (not a safety issue)

Conditions

Factor VII Deficiency
Glanzmann Thrombasthenia
Hemophilia A With Inhibitor

Interventions

BIOLOGICAL: Coagulation Factor VIIa variant

Sponsor

Catalyst Biosciences